Thousands of people at higher risk of oesophageal cancer could be offered a quick, less invasive test closer to home under draft guidance from NICE published for consultation today (Monday 16 November ...
First NICE-recommended drug for anal cancer that has spread and cannot be removed through surgery recommended today and is available immediately on the NHS.
Evidence-based recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-low metastatic or unresectable breast cancer after chemotherapy in adults. This guidance updates and replaces NICE ...
There is a simple discount patient access scheme for mirdametinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
There is a simple discount patient access scheme for lisocabtagene maraleucel. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
There is a simple discount patient access scheme for garadacimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
There are commercial access agreements for enfortumab vedotin and pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...
Evidence-based recommendations on 12 standardised quality betula verrucosa pollen sublingual lyophilisate (12 SQ-Bet SLIT; Itulazax) for treating moderate to severe allergic rhinitis or conjunctivitis ...
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...
There is a simple discount patient access scheme for marstacimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...